A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder

European Neuropsychopharmacology

Volumn 18, Issue 9, 2008, Pages 639-645

  Mischoulon, David ^a   Best Popescu, Catherine ^a   Laposata, Michael ^a   Merens, Wendelien ^a   Murakami, Jessica L ^a   Wu, Shirley L ^a   Papakostas, George I ^a   Dording, Christina M ^a   Sonawalla, Shamsah B ^a   Nierenberg, Andrew A ^a   Alpert, Jonathan E ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Depression; DHA; Docosahexaenoic acid; Eicosapentaenoic acid; EPA; n 3; Omega 3

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

ADULT; ANOREXIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HUMAN; LIBIDO DISORDER; MAJOR DEPRESSION; MALE; OUTPATIENT; PRIORITY JOURNAL; RASH; SIDE EFFECT; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY ACIDS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 48749130377     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.04.011     Document Type: Article

References (29)

1. Adams P.B., Lawson S., Sanigorski A., and Sinclair A.J. Arachidonic acid to eicosapentaenoic acid ration in blood correlates positively with clinical symptoms of depression. Lipids 31 (1996) 157-161
2. Cross-National Collaborative Group. The changing rate of major depression: cross national comparisons. JAMA 268 (1992) 3098-3105
3. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W. (1995) Structured Clinical Interview for Axis I DSM-IV Disorders - Patient Edition (With Psychotic Screen) (SCID-I/P (w/ psychotic screen)) (Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, 722 West 168th Street, New York, NY 10032.
4. Frangou S., Lewis M., and Mccrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br. J. Psychiatry 188 (2006) 46-50
5. Freeman M.P., Hibbeln J.R., Wisner K.L., Brumbach B.H., Watchman M., and Gelenberg A.J. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr. Scand. 113 (2006) 31-35
6. Freeman M.P., Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., Keck Jr. P.E., Marangell L.B., Richardson A.J., Lake J., and Stoll A.L. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 67 (2006) 1954-1967
7. In: Guy W. (Ed). ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM) 76-338 (1976), National Institute of Mental Health, Rockville, MD
8. Hibbeln J.R. Fish consumption and major depression. [Letter]. Lancet 351 (1998) 1213
9. Hibbeln J.R. Long-chain polyunsaturated fatty acids in depression and related conditions. In: Peet M., Glen I., and Horrobin D.F. (Eds). Phospholipid Spectrum Disorder in Psychiatry (1999), Marius Press, Carnforth, England 195-210
10. Hibbeln J.R., and Salem Jr. N. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am. J. Clin. Nutr. 62 (1995) 1-9
11. Keck Jr. P.E., Mintz J., McElroy S.L., Freeman M.P., Suppes T., Frye M.A., Altshuler L.L., Kupka R., Nolen W.A., Leverich G.S., Denicoff K.D., Grunze H., Duan N., and Post R.M. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol. Psychiatry 60 (2006) 1020-1022
12. Leon A.C. Descriptive and inferential statistics. In: Bellack A.S., and Hersen M. (Eds). Comprehensive Clinical Psychology (1998), Pergamon, Oxford 243-285
13. Marangell L.B., Martinez J.M., Zboyan H.A., Kertz B., Kim H.F., and Puryear L.J. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am. J. Psychiatry 160 (2003) 996-998
14. Marangell L.B., Martinez J.M., Zboyan H.A., Chong H., and Puryear L.J. Omega-3 fatty acids for the prevention of postpartum depression: negative data from a preliminary, open-label pilot study. Depress. Anxiety 19 (2004) 20-23
15. Moser H.W., and Moser A.B. Measurement of saturated very long chain fatty acids in plasma. Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual (1991), Wiley-Liss Inc., New York 177-191
16. Nemets B., Stahl Z.M., and Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry 159 (2002) 477-479
17. Nemets H., Nemets B., Apter A., Bracha Z., and Belmaker R.H. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am. J. Psychiatry 163 (2006) 1098-1100
18. Osher Y., Bersudsky Y., and Belmaker R.H. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J. Clin. Psychiatry 66 (2005) 726-729
19. Parker G., Gibson N.A., Brotchie H., Heruc G., Rees A.M., and Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am. J. Psychiatry 163 (2006) 969-978
20. Peet M., and Horrobin D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry 59 (2002) 913-919
21. Serhan C.N., and Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6 (2005) 1191-1197
22. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., and Moussignac R.L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196 (2002) 1025-1037
23. Silvers K.M., Woolley C.C., Hamilton F.C., Watts P.M., and Watson R.A. Randomized double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot. Essent. Fat. Acids 72 (2005) 211-218
24. Stoll A.L., and Locke C.A. Omega-3 fatty acids in mood disorders: a review of neurobiological and clinical actions. In: Mischoulon D., and Rosenbaum J. (Eds). Natural Medications for Psychiatric Disorders (2002), Lippincott Williams & Wilkins, Philadelphia 13-34
25. Stoll A.L., Severus W.E., Freeman M.P., Rueter S., Zboyan H.A., Diamond E., Cress K.K., and Marangell L.B. Omega3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 56 (1999) 407-412
26. Su K.P., Huang S.Y., Chiu C.C., and Shen W.W. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 13 (2003) 267-271
27. Sublette M.E., Hibbeln J.R., Galfalvy H., Oquendo M.A., and Mann J.J. Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. Am. J. Psychiatry 163 (2006) 1100-1102
28. Williams J.B. A structured interview guide for the Hamilton Depression Rating Scale. Arch. Gen. Psychiatry 45 (1988) 742-747
29. Wozniak J., Biederman J., Mick E., Waxmonsky J., Hantsoo L., Best C., Cluette-Brown J.E., and Laposata M. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur. Neuropsychopharmacol. 17 (2007) 440-447